Trending Now
ABVC Biopharma Inc (NASDAQ: ABVC) Recently Issued an Update on PDC-1412
ABVC Biopharma Inc (NASDAQ: ABVC) recently issued an update of its PDC-1421 clinical study to its shareholders. The company announced that some of its...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Evofem Biosciences Inc (NASDAQ: EVFM) Gets Its AMPOWER Study in the...
Evofem Biosciences Inc (NASDAQ: EVFM) announced that data from its AMPOWER Study is now in the Journal of Sexual Medicine. Data from the Phase...
MAKE IT MODERN
LATEST REVIEWS
Adverum Biotechnologies Inc. (NASDAQ:ADVM) Says It Has Randomized Its First Patient...
Adverum Biotechnologies Inc. (NASDAQ:ADVM) has been at the helm of developing novel gene therapies for the treatment of serious ocular and rare diseases. The...
MAKE IT MODERN
PERFORMANCE TRAINING
Synthetic Biologics Inc (NYSE:SYN) begins Phase 1a Clinical Trial Of SYN-020 IAP By Dosing...
Synthetic Biologics Inc (NYSE:SYN) began phase 1a clinical study of SYN-020 IAP (Intestinal Alkaline Phosphatase) by dosing the first six patients.
Cures inflammation in the...
AC Immune SA (NASDAQ: ACIU) Hosted a Webinar About a-synuclein
AC Immune SA (NASDAQ: ACIU) hosted Dr. Oscar Hansson, a top research scientist, on a webinar about a-synuclein. This is a therapeutic target to...
Seres Therapeutics Inc (NASDAQ:MCRB) Will Report SER-109 Phase 3 Study Topline Data in August...
Seres Therapeutics Inc (NASDAQ:MCRB) (STI) reported a drop of 51.75% YoY to $6.45 million in Q2 2020.
Business update
STI expects to post SER-109 Phase 3...
Intellia Therapeutics Inc (NASDAQ: NTLA) Receives An Orphan Drug Designation From the FDA
Intellia Therapeutics Inc's (NASDAQ: NTLA) NTLA-5001 has received an orphan drug designation from the U.S FDA. The drug is for a cure for myeloid...
Actuate Therapeutics Recently Issued an Update on Its Phase Two Study of Elraglusib
Actuate Therapeutics recently executed a partnership with the University of Kansas Cancer Center to research and develop the elraglusib Drug. The partnership focuses on...
MAKE IT MODERN
